<DOC>
	<DOCNO>NCT02645942</DOCNO>
	<brief_summary>The investigator design intervention investigate potential role L-C lipid carbohydrate metabolism ( primary outcome ) precision noninvasively measurement : central blood pressure , pulse wave velocity peripheral arterial stiffness ( secondary outcome ) OSA patient .</brief_summary>
	<brief_title>L-carnitine Reducing Cardio-metabolic Risk Patients With Obstructive Sleep Apnea</brief_title>
	<detailed_description>After screen patient randomize 1:1 ratio either placebo group study group ( receive L-C 8-weeks ) . Randomization stratify patient : age , sex , BMI severity OSA . Randomized patient receive orally either placebo L-C day 8-weeks . All supplement pack white box . Because double-blind study , vial label contain unique identification number disclose patient investigator L-C matching placebo include . The daily amount L-C 1400 mg . The detailed composition product assess . All patient receive test product control visit month ask take day morning . The completion data check visit also via telephone study conduct . All concomitant medication use ( include herbal supplement ) record electronic database . The patient ask continue habitual diet . Moreover , also advise free withdraw participation study time , reason , without prejudice . The reason withdrawal date discontinuation record database . Any Adverse Event ( AE ) record accord Common Terminology Criteria Adverse Events v4.0 ( CTCAE ) , clinically significant AE , severe laboratory abnormality , intercurrent illness , medical condition indicate continued administration study medication best interest patient . The treatment administrate supervision experience nutritionist medical doctor . The anthropometrical biochemical measurement assessment diet , quality life sleep complete patient study visit , take place baseline ( screen visit ) , 4 week , post-intervention period ( week 8 ) 6-month follow-up .</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>diagnose OSA classify accord apnea hypopnea index ( AHI ) mild ( 5.014.9 ) , moderate ( 15.029.9 ) , severe ( ≥30.0 event per hour ) , treatment Continuous Positive Airway Pressure ( CPAP ) least 6 month study screening , disturb lipid metabolism ( accord National Health Nutrition Examination Survey : LDLC &gt; 100 mg/dl , TG &gt; 150 mg/dl ) use hypolipidemic drug , disturb glucose metabolism ( Diabetes mellitus impaired glucose tolerance impair fast glucose ) accord American Diabetes Federation use hypoglycaemic drug , willingness participate study , age 18 , continue habitual diet study period , performance status ≥ 80 accord Karnofsky score newly diagnose OSA individual treat CPAP , OSA lung dysfunction , use hypoglycaemic hypolipidemic drug , modification hypolipidemic hypoglycaemic treatment study period , pregnancy lactation , cancer ( exclude curatively treat evidence diseases 5 year ) , severe liver kidney disease ( Aspartate aminotransferase ( ASPAT ) alanine aminotransferase ( ALAT ) &gt; 3 × upper limit normal ( ULN ) , Bilirubin &gt; 1.5 × ULN , Creatinine &gt; 1.5 × ULN ) , know sensitivity component product , diagnose CVD ( myocardial infarct , stroke , angina pectoris ) . active drug alcohol abuse , legal incompetence , limited legal incompetence , uncontrolled medical condition may put studied patient high risk study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Carnitine</keyword>
	<keyword>placebo</keyword>
	<keyword>risk factor</keyword>
</DOC>